Back to mobile site
Get it on Google Play

FDA grants fast track status to Acadia drug for Alzheimer's psychosis

July 20, 2026 9:05 AM EDT Send to a Friend
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced that the U.S. Food and Drug Administration has granted Fast Track designation to remlifanserin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login